225 related articles for article (PubMed ID: 16725267)
21. Venous thromboembolic events and erythropoiesis-stimulating agents: an update.
Dicato M
Oncologist; 2008; 13 Suppl 3():11-5. PubMed ID: 18458119
[TBL] [Abstract][Full Text] [Related]
22. Anaemia management with epoetin alfa in lung cancer patients in The Netherlands.
Biesma B; van de Werf PR; Melissant CF; Brok RG
Lung Cancer; 2007 Oct; 58(1):104-11. PubMed ID: 17601632
[TBL] [Abstract][Full Text] [Related]
23. Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemia.
Szucs TD; Blank PR; Schwenkglenks M; Aapro M
Oncology; 2011; 81(1):45-9. PubMed ID: 21921645
[TBL] [Abstract][Full Text] [Related]
24. Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer.
Juneja V; Keegan P; Gootenberg JE; Rothmann MD; Shen YL; Lee KY; Weiss KD; Pazdur R
Clin Cancer Res; 2008 Jun; 14(11):3242-7. PubMed ID: 18519748
[TBL] [Abstract][Full Text] [Related]
25. Cancer-related anaemia management in the 21st century.
Pronzato P
Cancer Treat Rev; 2006; 32 Suppl 2():S1-3. PubMed ID: 16725269
[TBL] [Abstract][Full Text] [Related]
26. Early intervention with epoetin beta prevents severe anaemia in patients with solid tumours receiving platinum-based chemotherapy: results of the NeoPrevent study.
de Castro J; Ordóñez A; Isla D; Sánchez A; Arrivi A; Manzano JL; Barón MG
Cancer Chemother Pharmacol; 2007 Jan; 59(1):35-42. PubMed ID: 16874498
[TBL] [Abstract][Full Text] [Related]
27. Adherence to guidelines for use of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia: results of a retrospective study of an electronic medical-records database in the United States, 2002-2006.
Luo W; Nordstrom BL; Fraeman K; Nordyke R; Ranganathan G; Linz HE; Winterkorn A; Stokes M; Ross SD; Knopf K
Clin Ther; 2008 Dec; 30(12):2423-35. PubMed ID: 19167601
[TBL] [Abstract][Full Text] [Related]
28. Anemia profiles in patients with lung cancer: what have we learned from the European Cancer Anaemia Survey (ECAS)?
Kosmidis P; Krzakowski M;
Lung Cancer; 2005 Dec; 50(3):401-12. PubMed ID: 16191450
[TBL] [Abstract][Full Text] [Related]
29. Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?
Bormanis J; Quirt I; Chang J; Kouroukis CT; MacDonald D; Melosky B; Verma S; Couture F
Crit Rev Oncol Hematol; 2013 Aug; 87(2):132-9. PubMed ID: 23357249
[TBL] [Abstract][Full Text] [Related]
30. Use of erythropoiesis stimulating agents and intravenous iron for cancer and treatment-related anaemia: the need for predictors and indicators of effectiveness has not abated.
Katodritou E; Zervas K; Terpos E; Brugnara C
Br J Haematol; 2008 Jul; 142(1):3-10. PubMed ID: 18430192
[TBL] [Abstract][Full Text] [Related]
31. Recombinant human erythropoietin beta therapy: an effective strategy to reduce transfusion requirement in children receiving anticancer treatment.
Corapcioglu F; Aksu G; Basar EZ; Demirel A; Oncel S; Mutlu A
Pediatr Hematol Oncol; 2008 Sep; 25(6):509-21. PubMed ID: 18728970
[TBL] [Abstract][Full Text] [Related]
32. Update on erythropoiesis-stimulating agents and clinical trials in oncology.
Aapro M; Spivak JL
Oncologist; 2009; 14 Suppl 1():6-15. PubMed ID: 19762512
[TBL] [Abstract][Full Text] [Related]
33. Utilisation review of epoetin alfa in cancer patients at a cancer centre in Singapore.
Chan A; Lim LL; Tao M
Singapore Med J; 2009 Apr; 50(4):365-70. PubMed ID: 19421679
[TBL] [Abstract][Full Text] [Related]
34. A prospective observational study of anaemia management in cancer patients - results from the German Cancer Anaemia Registry.
Steinmetz T; Totzke U; Schweigert M; Mittermüller J; Nawka S; Tesch H; Groschek M; Söling U; Hellebrand E; Tsamaloukas A
Eur J Cancer Care (Engl); 2011 Jul; 20(4):493-502. PubMed ID: 21029222
[TBL] [Abstract][Full Text] [Related]
35. Reassessments of ESAs for cancer treatment in the US and Europe.
Bennett CL; McKoy JM; Henke M; Silver SM; MacDougall IC; Birgegård G; Luminari S; Casadevall N; Schellekens H; Sartor O; Lai SY; Armitage JO
Oncology (Williston Park); 2010 Mar; 24(3):260-8. PubMed ID: 20394138
[TBL] [Abstract][Full Text] [Related]
36. Management of anemia in cancer patients.
Calabrich A; Katz A
Future Oncol; 2011 Apr; 7(4):507-17. PubMed ID: 21463140
[TBL] [Abstract][Full Text] [Related]
37. Early intervention with epoetin beta prevents severe anaemia in lung cancer patients receiving platinum-based chemotherapy: a subgroup analysis of the NeoPrevent study.
de Castro J; Belda-Iniesta C; Isla D; Dómine M; Sánchez A; Batiste E; Barón MG
Lung Cancer; 2008 Feb; 59(2):211-8. PubMed ID: 17875340
[TBL] [Abstract][Full Text] [Related]
38. Erythropoiesis-stimulating agents in cancer patients: reflections on safety.
Wauters I; Vansteenkiste J
Expert Rev Clin Pharmacol; 2011 Jul; 4(4):467-76. PubMed ID: 22114856
[TBL] [Abstract][Full Text] [Related]
39. Risks and benefits of erythropoiesis-stimulating agents in cancer management.
Beutel G; Ganser A
Semin Hematol; 2007 Jul; 44(3):157-65. PubMed ID: 17631180
[TBL] [Abstract][Full Text] [Related]
40. Safety update on erythropoiesis-stimulating agents: trials within and outside the accepted indications.
Gascón P
Oncologist; 2008; 13 Suppl 3():4-10. PubMed ID: 18458118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]